кто такие по натуре раки

Nature Reviews CancerISSN: 1474-175XEISSN: 1474-1768

This figure indicates the potential of immunogenetic therapy, which involves stimulation of the cellular immune system to recognize and destroy cancer cells. a | Transfection of isolated tumour cells with genes encoding a variety of cytokines — such as interleukin-2 (IL-2) and granulocyte–macrophage colony-stimulating factor (GM-CSF) — or co-stimulatory molecules (such as CD80 and CD86). The transfected genes increase the immunogenicity of the autologous tumour cells, which potentially display a range of tumour-specific antigens, and increase the likelihood of generating a tumour-specific cytotoxic T-lymphocyte (CTL) response. b | Ex vivo transfection of antigen-presenting cells (APCs) with a gene encoding a tumour-specific antigen (such as carcinoembryonic antigen, CEA), which is presented by major histocompatibility complex (MHC) class I molecules to antigen-specific CTLs via the T-cell receptor (TCR). Stimulated CTLs can seek out and destroy residual CEA-expressing tumour cells. GM-CSF can increase the activation of APCs and their migration into the tumour tissue.Download fileIf the slide opens in your browser, select "File > Save As" to save it.

> > > Figure 4FIGURE 4 | Immunogenetic therapy for colorectal cancer.From the following article: David KerrNature Reviews Cancer 3, 615-622 (August 2003)doi:10.1038/nrc1147

Figure 4 : Clinical development of gene therapy for colorectal cancer : Nature Reviews Cancer